AVEO News and Press, AVEO Pharmaceuticals Inc. From 08/15/22

Today, we put small oncology name AVEO Pharmaceuticals in the spotlight for the first time in three and a half years. The company is seeing good sales growth from its franchise drug that was approved in 2021 and is marching toward profitability as a company. An investment analysis...

AVEO Pharmaceuticals, Inc. (AVEO) Q2 2022 Earnings Conference Call August 04, 2022 04:30 PM ET Company Participants Hans Vitzthum - LifeSci Advisors Michael Bailey - President & Chief Executive Officer Mike Ferraresso - Chief Commercial Officer Erick Luce...

– Total Q2 2022 Net Revenue of $25.3 million including $25.0 million of FOTIVDA ® (tivozanib) U.S. Net Product Revenue – – Q2 2022 FOTIVDA U.S. Net Product Revenue Growth of 24% C ompared with Q1 2022 – – Comp...

BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022. AVEO’s management team will host a confe...

- This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada - - AVEO Currently Manufacturing Ficlatuzumab Clinical Supply; Potential Phase 3 Registrational Clin...

BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy ...

Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated a 55% reduction in risk of death on tivozanib as compared to sorafenib Latest analysis of Phase 2 study show tivozanib demonstrated promising activity in...

AVEO is a mostly forgotten name that is seeing very good growth in their lead product FOTIVDA. Their share price has run lower from exuberant highs reached almost 5 years ago, even as their fundamentals and future seem to be getting more solid. AVEO seems like a mostly forgotten a...

BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednes...

AVEO Pharmaceuticals, Inc. (AVEO) Q1 2022 Earnings Conference Call May 05, 2022 8:00 AM ET Company Participants Hans Vitzthum – LifeSci Advisors Michael Bailey – President and Chief Executive Officer Mike Ferraresso – Chief Commercial Officer Erick Lucera – Chief F...